Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone

Proceedings of the National Academy of Sciences of the United States of America

Volumn 94, Issue 4, 1997, Pages 1420-1425

  Kovacs, Magdolna ^a,b,c   Schally, Andrew V ^a,b   Nagy, Attila ^a,b   Koppan, Miklos ^a,b,c   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

growth hormone; pituitary hormones; selective damage; targeted chemotherapy; thyrotropin

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 2117; DOXORUBICIN DERIVATIVE; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GROWTH HORMONE; LUTEINIZING HORMONE; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SPECIFICITY; CYTOPATHOGENIC EFFECT; DRUG EFFECT; DRUG SPECIFICITY; FEMALE; GONADOTROPIN SECRETING CELL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; INTRAVENOUS DRUG ADMINISTRATION; LUTEINIZING HORMONE RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; THYROTROPIN RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CYTOTOXINS; DOXORUBICIN; FEMALE; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; PITUITARY FUNCTION TESTS; PITUITARY GLAND, ANTERIOR; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; THYROTROPIN;

ANIMALIA;

EID: 0031029918     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.94.4.1420     Document Type: Article

References (28)

1. Schally, A. V., Nagy, A., Szepeshazi, K., Pinski, J., Halmos, G., Armatis, P., Miyazaki, M., Comaru-Schally, A. M., Yano, T. & Emons, G. (1996) in Treatment with Gn-RH Analogs: Controversies and Perspectives, eds. Filicori, M. & Flamigni, C. (Parthenon, Carnforth, U.K.), pp. 33-44.
2. Schally, A. V. & Comaru-Schally, A. M. (1997) in Cancer Medicine, eds. Holland, J. F., Frei, E., Bast, R. C., Kufe, D. W., Morton, D. L. & Weichselbaum, R. R. (Williams & Wilkins, Baltimore), 4th Ed., pp. 1067-1086.
3. Schally, A. V. (1994) Anti-Cancer Drugs 5, 115-130.
4. Yano, T., Pinski, J., Halmos, G., Szepeshazi, K., Groot, K. & Schally, A. V. (1994) Proc. Natl. Acad. Sci. USA 91, 7090-7094.
5. Qayum, A., Gullick, W., Clayton, R. C., Sikora, K. & Waxman, J. (1990) Br. J. Cancer 62, 96-99.
6. Fekete, M., Redding, T. W., Comaru-Schally, A. M., Pontes, A. E., Connelly, R. W., Srkalovic, G. & Schally, A. V. (1989) Prostate 14, 191-208.
7. Schally, A. V., Comaru-Schally, A. M. & Gonzalez-Barcena, D. (1992) Biomed. Pharmacother. 46, 465-471.
8. Fekete, M., Wittliff, J. L. & Schally, A. V. (1989) J. Clin. Lab. Anal. 3, 137-147.
9. Emons, G. & Schally, A. V. (1994) Hum. Reprod. 9, 1364-1379.
10. Emons, G., Ortmann, O., Becker, M., Irmer, G., Springer, B., Laun, R., Holzel, F., Schulz, K. D. & Schally, A. V. (1993) Cancer Res. 53, 5439-5446.
11. Emons, G., Schroder, B., Ortmann, O., Westphalen, S., Schulz K. D. & Schally, A. V. (1993) J. Clin. Endocrinol. Metab. 77, 1458-1464.
12. Schally, A. V., Radulovic, S. & Comaru-Schally, A. M. (1993) in Experimental and Clinical Studies in Hormone Dependent Cancers, eds. Mazzaferri, E. & Samaan, N. (Blackwell, Boston), pp. 49-73.
13. Harris, N., Dutlow, C., Eidne, K., Dong, K.-W. & Millar, R. (1991) Cancer Res. 51, 2577-2581.
14. Fitzgerald, D. & Pastan, I. (1989) J. Natl. Cancer Inst. 81, 1455-1463.
15. Pinski, J., Schally, A. V., Yano, T., Szepeshazi, K., Halmos, G., Groot, K., Comaru-Schally, A. M., Radulovic, S. & Nagy, A. (1993) Prostate 23, 165-178.
16. Szepeshazi, K., Schally, A. V., Halmos, G., Szoke, B., Groot, K. & Nagy, A. (1996) Breast Cancer Res. Treat. 40, 129-139.
17. Nagy, A., Armatis, P. & Schally, A. V. (1996) Proc. Natl. Acad. Sci. USA 93, 2464-2469.
18. Nagy, A., Schally, A. V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A. & Horvath, J. (1996) Proc. Natl. Acad. Sci. USA 93, 7269-7273.
19. Jungwirth, A., Schally, A. V., Nagy, A., Pinski, J., Groot, K., Galvan, G., Szepeshazi, K. & Halmos, G. (1996) Cancer Res., in press.
20. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254.
21. Csernus, V. J. & Schally, A. V. (1991) in Neuroendocrine Research Methods, ed. Greenstein, B. D. (Harwood, London), pp. 71-109.
22. Miller, W. R., Scott, W. N., Morris, R., Fraser, H. M. & Sharpe, R. M. (1985) Nature (London) 313, 231-233.
23. Pigram, W. J., Fuller, W. & Hamilton, L. D. (1972) Nature (London) New Biol. 235, 17-19.
24. Moore, W. H. (1977) Science 197, 527-532.
25. Tritton, T. R. & Yee, G. (1982) Science 217, 248-250.
26. Tritton, T. R. (1991) Pharmacol. Ther. 49, 293-309.
27. Rekasi, Z., Szoke, B., Nagy, A., Groot, K., Rekasi, E. S. & Schally, A. V. (1993) Endocrinology 132, 1991-2000.
28. Shalet, S. M. (1996) Eur. J. Endocrinol. 135, 135-143.